FDA approves Sun's generic Exelon

MUMBAI, India The Food and Drug Administration has granted final approval for Sun Pharmaceutical’s application to market a generic version of Novartis’s Exelon.

The drug, rivastgmine tartrate, is used to treat mild to moderate dementia associated with Alzheimer’s and Parkinson’s disease.

The generic will be available in all four strengths and the company will share a 180-day exclusivity for the drug which had annual sales of about $200 million.

Login or Register to post a comment.